8-K: Tivic Health Secures Key Drug Applications for Entolimod

Tivic Health Systems, Inc. announced the completion of the transfer of two investigational new drug applications (INDs) for its lead candidate, Entolimod, from Statera Biopharma, Inc.

Summary

• Tivic Health Systems, Inc. completed the transfer of two Investigational New Drug Applications (INDs) for its lead candidate, Entolimod, from Statera Biopharma, Inc.
• The transferred INDs cover Entolimod's use for acute radiation syndrome (ARS), including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes.
• The INDs also cover Entolimod's use for advanced cancers, specifically as an anti-tumor agent and for conditions resulting from cancer treatments.
• Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms.
• Under the FDA's Animal Rule, Entolimod has demonstrated robust survival, enhanced GI tract recovery, and improved hematopoiesis in animal models for ARS.
• Entolimod has been granted Fast Track Designation for ARS by the FDA.
• Tivic holds exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome.

Sentiment

Score: 8

Explanation: The successful transfer of two INDs for a lead candidate, Entolimod, which already has Fast Track Designation for a critical indication (ARS) and shows promise in animal models, significantly de-risks and advances Tivic Health's pipeline. This enables further clinical development and regulatory engagement, which are crucial milestones for a biopharmaceutical company.

Positives

• Completed the transfer of two Investigational New Drug Applications (INDs) for Entolimod, advancing its regulatory pathway.
• Entolimod's INDs cover two significant indications: acute radiation syndrome and advanced cancers.
• Entolimod has been granted Fast Track Designation for acute radiation syndrome (ARS), which can accelerate its development and regulatory review.
• The IND transfer enables formal engagement with the FDA regarding Entolimod's regulatory pathway.
• The transfer enables the pursuit of clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions.
• Entolimod has demonstrated robust survival, enhanced GI tract recovery, and improved hematopoiesis in animal models for ARS.
• Tivic holds exclusive rights for Entolimod for neutropenia and options to license additional indications.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially.
• Risks include those related to interactions with and guidance from the FDA and other regulatory authorities.
• Changes to the company's relationship with its partners could adversely affect outcomes.
• Uncertainties exist regarding the timing and success of clinical trials and study results.
• There is a risk of failure to obtain FDA or similar clearances or approvals and noncompliance with regulations.
• Future development of the company's ncVNS treatment, Entolimod, and Entolasta is subject to risks.
• Changes to the company's business strategy could impact performance.
• Regulatory requirements and pathways for approval pose inherent risks.
• The company's need for, and ability to secure when needed, additional working capital is a risk factor.
• Maintaining the Nasdaq listing is a potential risk.
• Changes in tariffs, inflation, legal, regulatory, political, and economic risks could affect the business.

Future Outlook

The IND transfer allows formal engagement with the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions. The company's near-term focus for Entolimod remains acute radiation syndrome.

Management Comments

• "Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions." Jennifer Ernst, CEO.
• "While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome." Jennifer Ernst, CEO.

Industry Context

This announcement positions Tivic Health as an active player in the immunotherapeutics space, specifically targeting critical unmet medical needs like acute radiation syndrome and advanced cancers. The acquisition of INDs from Statera Biopharma indicates strategic asset consolidation and advancement of a late-stage drug candidate (Entolimod with Fast Track designation) in a competitive biopharma landscape. The dual platform strategy (biopharmaceutical and bioelectronic) suggests a diversified approach to immune system modulation.

Comparison to Industry Standards

• Entolimod's Fast Track Designation for ARS is a significant regulatory advantage, similar to other companies with promising drug candidates addressing serious conditions with unmet needs.
• The 'Animal Rule' pathway for ARS development is a specific regulatory route used for products that cannot be ethically tested in humans, common for biodefense countermeasures.
• The company's dual platform strategy (biologics and bioelectronics) is a less common but potentially synergistic approach compared to companies focused solely on small molecules or biologics.

Stakeholder Impact

• Shareholders: Positive impact due to advancement of a key drug candidate, potential for future value creation, and de-risking of the pipeline.
• Patients: Potential for new treatments for acute radiation syndrome, advanced cancers, neutropenia, and lymphocyte exhaustion.
• Employees: Continued focus on drug development and potential for growth.
• Regulatory Authorities (FDA): Will be engaged for regulatory pathway discussions and clinical trial approvals.

Next Steps

• Formally engage the FDA regarding Entolimod's regulatory pathway.
• Initiate clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions.
• Continue focus on Entolimod's first indication: acute radiation syndrome.

Key Dates

Recommendation

The successful transfer of two Investigational New Drug (IND) applications for Entolimod, a lead candidate with Fast Track Designation for Acute Radiation Syndrome, represents a significant de-risking event and a clear advancement in Tivic Health's pipeline. This milestone enables crucial clinical development and regulatory engagement, which are key value drivers for a biopharmaceutical company. While risks inherent to drug development remain, this development provides a strong positive signal for future growth and potential market opportunities in critical unmet medical needs.

Keywords

Tivic Health, Entolimod, IND, Investigational New Drug, Acute Radiation Syndrome, ARS, Cancer Treatment, TLR5 agonist, Fast Track Designation, Biopharma, Immunotherapeutics, Nasdaq, TIVC, Statera Biopharma, Neutropenia, Lymphocyte Exhaustion, FDA